News
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Duc Binh Phan, Anthony P Bewley, Catherine H Smith, Teena Mackenzie, Christopher E M Griffiths, Mark Lunt, Richard B Warren, Zenas Z N Yiu British Journal of Dermatology, Volume 189, Issue 1, July 2023, Pages 62–70, https://doi.org/10.1093/bjd/ljad107Published: 05...
Centre of the month: June 2024
Hull University Teaching Hospitals NHS Trust was selected for their hard work resolving queries and getting patients up-to-date. A message from Hull: BADBIR has shown how effective team working helps clinicians and patients provide safe and quality care for our...
Centre of the month: February 2024
Ashford and St Peter's NHS Foundation Trust was selected for their hard work keeping on top of outstanding follow-ups. A message from Ashford and St Peter's: We are really proud to have been selected as the BADBIR centre of the month. Our team has worked really hard...
Recruitment open to Spevigo (spesolimab)
We are now accepting patients on Spevigo (spesolimab). Spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (GPP). BADBIR can accept registrations for patients with a GPP diagnosis.Please see the eligibility page for...
Recruitment re-open to Stelara, Humira, Amgevita, Hulio, Hyrimoz, Idacio, Yuflyma
BADBIR is now open to registrations of patients commencing on the following drugs: Stelara (ustekinumab), Humira (adalimumab), Amgevita (adalimumab), Hulio (adalimumab), Hyrimoz (adalimumab), Idacio (adalimumab) and Yuflyma (adalimumab).
A sprinkle of methotrexate to go with biologics: a safe recipe?
Oras A Alabas, Zenas Z N Yiu British Journal of Dermatology, Volume 190, Issue 3, March 2024, Pages 302–303 https://doi.org/10.1093/bjd/ljad505 Related Contact Us Tel: +44 (0)161 306 1896 Email: badbir@manchester.ac.uk Find Us The...
Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis
JAMA Dermatology, 2023.Ali Al-Janabi; Oras A. Alabas; Zenas Z. N. Yiu; Amy C. Foulkes; Steve Eyre; Adnan R. Khan; Nick J. Reynolds; Catherine H. Smith; Christopher E. M. Griffiths; Richard B. Warren; the BADBIR Study Group.Read publication: JAMA Dermatology Related...
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
BJD, 2023.Oras A. Alabas, Kayleigh J. Mason, Zenas Z.N. Yiu, Richard B. Warren, Nick Dand, Jonathan N.W.N. Barker, Catherine H. Smith, Christopher E.M. Grifï¬ths, the BADBIR and BSTOP study group.Read publication: BJD Related Contact Us...
Characteristics of “super responders” and “super nonresponders” to first biologic monotherapy for psoriasis: a nested case-control study
BJD, 2023.Kayleigh J. Mason, Oras A. Alabas, Nick Dand, Richard B. Warren, Nick J. Reynolds, Jonathan N.W.N. Barker, Zenas Z. N. Yiu, Catherine H. Smith, Christopher E.M. Griffiths, the BADBIR Study Group.Read publication: BJD Related ...
Password policy updates to the BADBIR Database
In our ongoing commitment to maintaining a secure and user-friendly online environment, we are updating our password policy. We kindly request all our users to consider reviewing and enhancing the strength of their passwords in preparation for the new criteria, which...